#dolutegravir

[mrberkqy]

Mesela cennet yoksa, tek hayat buysa, yaşamak lazımsa çok geçmeden?

[gecenin-karanligi-21]

Bütün meleklerinin kanadını kendisi kıracaktı. En büyük günahlar hep melek olanlarındı

[chemanalystdata]

Dolutegravir Prices | Pricing | Trend | News | Database | Chart | Forecast

Dolutegravir is an antiretroviral medication primarily used in the treatment of HIV/AIDS. As part of the class of drugs known as integrase inhibitors, Dolutegravir works by blocking the action of an enzyme called integrase, which the HIV virus uses to replicate. Since its approval by the U.S. Food and Drug Administration (FDA) in 2013, Dolutegravir has become a crucial component in many HIV treatment regimens. However, one of the most significant concerns around the world, especially in low-income and middle-income countries, has been the pricing of Dolutegravir. Pricing influences access to this essential medication, and efforts are ongoing to make it more affordable for those who need it most.

The cost of Dolutegravir varies widely depending on geographic location, patent laws, and whether the drug is branded or generic. In high-income countries such as the United States, Dolutegravir is often sold under the brand name Tivicay, manufactured by ViiV Healthcare. The brand-name version of Dolutegravir tends to be expensive, with prices in the U.S. being notably higher than in other regions. For example, a month's supply of Tivicay can cost thousands of dollars. This high cost is driven by research and development expenses, regulatory costs, and the need to recoup the investment in bringing a new drug to market. However, the high cost in wealthier nations often makes it difficult for those without adequate health insurance or government assistance to access the medication.

Get Real Time Prices for Dolutegravir  : https://www.chemanalyst.com/Pricing-data/dolutegravir-1534

In contrast, many low- and middle-income countries rely on generic versions of Dolutegravir, which are significantly less expensive. Generic Dolutegravir became available after licensing agreements and patent waivers were negotiated between pharmaceutical companies, non-governmental organizations, and international agencies. These agreements allowed for the production of more affordable versions of the drug, making it accessible to larger populations. In countries such as India, which has a robust generic pharmaceutical industry, the price of Dolutegravir can be as low as a few dollars per month. This drastic reduction in price has been crucial in improving access to HIV treatment, particularly in regions that are heavily burdened by the epidemic, such as sub-Saharan Africa.

Global health organizations like the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have played a pivotal role in advocating for lower prices for HIV medications, including Dolutegravir. The Medicines Patent Pool (MPP) is another initiative that has helped to lower the cost of Dolutegravir. By facilitating voluntary licensing agreements, the MPP enables generic drug manufacturers to produce and sell Dolutegravir at a fraction of the price of the branded version. These efforts have resulted in broader availability of the drug, but challenges remain in ensuring that everyone who needs Dolutegravir can afford it.

The introduction of Dolutegravir as part of first-line HIV treatment regimens in many countries has been a game-changer. Not only is Dolutegravir highly effective in suppressing the HIV virus, but it also has a high barrier to resistance, meaning that patients are less likely to develop resistance to the drug over time. Moreover, Dolutegravir has fewer side effects compared to older antiretroviral medications, making it a preferred option for many patients and healthcare providers. Given its effectiveness, there has been a global push to make Dolutegravir the standard of care in HIV treatment. However, pricing remains a barrier in some parts of the world, where even the generic versions may be out of reach for the most vulnerable populations.

Efforts to reduce the price of Dolutegravir are ongoing, with various international partnerships and coalitions working to negotiate lower costs. For example, the Global Fund to Fight AIDS, Tuberculosis and Malaria has been instrumental in securing lower prices for Dolutegravir through bulk purchasing agreements. These agreements allow for large quantities of the drug to be purchased at a reduced cost, which can then be distributed to countries in need. Additionally, some countries have implemented pricing controls or subsidies to make Dolutegravir more affordable for their populations. These strategies have been successful to varying degrees, depending on the political and economic landscape of each country.

Another factor influencing the price of Dolutegravir is the expiration of patents. As patents on the drug begin to expire in more countries, the opportunity for increased competition among generic manufacturers grows. This competition is expected to drive prices down even further, making Dolutegravir more accessible to a wider range of people. However, patent expirations are staggered across different regions, meaning that some countries may experience price reductions sooner than others. In countries where the patent is still in effect, advocacy efforts are focused on encouraging pharmaceutical companies to voluntarily lower their prices or enter into more licensing agreements that would allow for the production of generics.

In recent years, there has been a growing emphasis on the importance of affordable HIV treatment as part of global health initiatives. The United Nations has set ambitious goals for reducing the number of new HIV infections and ensuring that those living with HIV have access to treatment. Dolutegravir is central to these efforts, but its price remains a critical issue. Without continued pressure on pharmaceutical companies and governments, there is a risk that some populations will continue to be left behind in the fight against HIV/AIDS.

In conclusion, the pricing of Dolutegravir reflects a complex interplay of factors, including patent laws, production costs, and global health policies. While progress has been made in making the drug more affordable, particularly in low- and middle-income countries, there is still work to be done to ensure that everyone who needs Dolutegravir can access it. The future of HIV treatment depends not only on the development of new and effective medications but also on the ability to make these treatments affordable and accessible to all. Through continued international cooperation and advocacy, it is possible to further reduce the price of Dolutegravir and ensure that it reaches those who need it most.

Get Real Time Prices for Dolutegravir  : https://www.chemanalyst.com/Pricing-data/dolutegravir-1534

Contact Us:

ChemAnalyst

GmbH - S-01, 2.floor, Subbelrather Straße,

15a Cologne, 50823, Germany

Call: +49-221-6505-8833

Email: sales@chemanalyst.com

Website: https://www.chemanalyst.com

[pharmaceutical0]

Dolutegravir

Simson Pharma provides best quality Dolutegravir.

Every compound produced by Simson Pharma is accompanied by Certificate of Analysis.

https://www.simsonpharma.com/product/dolutegravir

[russianreader]

HIV Is on the Rise Again in Russia

The number of new cases of HIV infection in Russia has been growing again. In 2022, 63,150 people were diagnosed with HIV, while a year earlier this figure was 61,098 people, according to the Russian Health Ministry. During the pandemic, fewer cases of HIV infection were detected in Russia due to reduced testing coverage and lockdowns. The HIV detection rate in Russia increased by eight percent…

[chemanalystdata]

Dolutegravir Prices, Pricing, Trend, Supply & Demand and Forecast | ChemAnalyst

Dolutegravir Prices a revolutionary antiretroviral medication used in the treatment of HIV/AIDS, has garnered significant attention in recent years due to its efficacy and accessibility concerns. This integrase inhibitor has emerged as a frontline drug in combating the HIV epidemic, offering potent viral suppression with fewer side effects compared to previous therapies. However, amidst its clinical success, the pricing of dolutegravir has become a contentious issue, posing challenges for patients, healthcare systems, and advocacy groups worldwide.

The cost of dolutegravir has been a focal point of debate, particularly in low- and middle-income countries where access to affordable medication is critical. Developed by pharmaceutical company ViiV Healthcare, dolutegravir's pricing strategies have drawn scrutiny, with concerns raised over its affordability and accessibility for those in need. Despite efforts to negotiate lower prices for generic versions, the expense of patented dolutegravir remains a barrier for many individuals living with HIV/AIDS, especially in resource-limited settings.

In high-income countries, the price of dolutegravir is often managed through healthcare systems or insurance coverage, mitigating the financial burden on patients. However, even in these settings, the cost of treatment can strain healthcare budgets, prompting discussions on value-based pricing and cost-effectiveness. Additionally, concerns have been raised regarding potential price hikes and monopolistic practices by pharmaceutical companies, which could further exacerbate the financial challenges associated with accessing dolutegravir.

Get Real Time Prices of Dolutegravir: https://www.chemanalyst.com/Pricing-data/dolutegravir-1534

The situation is more acute in low- and middle-income countries, where the affordability of essential medications like dolutegravir directly impacts public health outcomes. While initiatives such as the Medicines Patent Pool seek to facilitate access to generic versions of dolutegravir, patent restrictions and licensing agreements can limit the availability of affordable alternatives. This leaves governments, healthcare organizations, and advocacy groups grappling with the dilemma of balancing treatment access with the financial constraints of healthcare budgets.

Despite these challenges, progress has been made in expanding access to dolutegravir through various channels. Strategic partnerships between pharmaceutical companies, governments, and international organizations have led to price reductions and voluntary licensing agreements, enabling broader availability of the medication. Moreover, advocacy efforts by civil society groups have highlighted the importance of equitable access to essential medicines, amplifying the voices of those affected by high drug prices.

In addition to pricing concerns, the safety and efficacy of dolutegravir have also come under scrutiny, particularly regarding potential side effects such as neural tube defects in pregnant individuals. While studies have shown dolutegravir to be highly effective in viral suppression, ongoing research is needed to better understand its long-term effects and optimal use in diverse patient populations. This underscores the importance of comprehensive healthcare strategies that address both affordability and safety considerations.

Looking ahead, addressing the pricing of dolutegravir requires a multi-stakeholder approach that considers the interests of patients, healthcare providers, policymakers, and pharmaceutical companies. Efforts to promote transparency in drug pricing, foster competition through generic production, and advocate for equitable access to essential medicines are essential components of this endeavor. Furthermore, investment in research and development of alternative treatment options can help diversify the HIV/AIDS therapeutic landscape and mitigate reliance on high-priced medications.

In conclusion, while dolutegravir represents a significant advancement in HIV/AIDS treatment, its pricing presents complex challenges that necessitate collaborative solutions. By prioritizing affordability, accessibility, and safety, stakeholders can work towards ensuring that individuals living with HIV/AIDS have access to the medications they need to lead healthy and productive lives. As the global community continues its fight against the HIV epidemic, addressing the pricing of dolutegravir remains a critical imperative in advancing public health and healthcare equity.

Get Real Time Prices of Dolutegravir: https://www.chemanalyst.com/Pricing-data/dolutegravir-1534

Contact Us:

ChemAnalyst

GmbH - S-01, 2.floor, Subbelrather Straße,

15a Cologne, 50823, Germany

Call: +49-221-6505-8833

Email: sales@chemanalyst.com

Website: https://www.chemanalyst.com

[reasonsforhope]

"A first-of-its-kind report has discovered that altering the ingredients list or manufacturing methods of widely used medication can really cut back on carbon emissions.

They found a reduction of 26 million tons, enough to cancel out the whole carbon footprint of the city of Geneva for a decade. Best of all, it’s already happening, and in fact, is almost done—those emissions were already saved.

The lifesaving HIV treatment dolutegravir (DTG) is used by 24 million people worldwide.

Today, over 110 low and middle-income countries have adopted DTG as the preferred treatment option. Rapid voluntary licensing of the medicine, including its pediatric version, to over a dozen generic manufacturers, significantly drove down prices, and it’s estimated that 1.1 million lives will be saved from HIV/AIDS-related deaths by 2027.

Its predecessor, efavirenz, contained 1200 milligrams of active ingredient across the three active compounds present, while DTG contains 650 milligrams of just one compound. This small difference—literally measurable in single digits of paper clips by weight—was enough to change the carbon emissions footprint of the medication by a factor of 2.6.

The incredible discovery was made in a recent report by Unitaid, a global public-private partnership that invests in new health products and solutions for low and middle-income countries, called Milligrams to Megatons, and is the first published research to compare carbon footprints between commonly used medications.

“This magnitude of carbon footprint reduction surpasses many hard-won achievements of climate mitigation in health and other sectors,” the authors of the report write.

At the rate at which DTG is produced, since it entered into production and treatment regime in 2017, 2.6 million fewer tons of CO2 have entered the atmosphere every year than if efavirenz was still the standard treatment option.

Health Policy Watch reports that the global medical sector’s carbon emissions stand at roughly 5% of the global carbon emissions and are larger than the emissions of many big countries, and 2.5 times as much as aviation.

“This report demonstrates that we can achieve significant health improvements while also making strides in reducing carbon emissions. By adopting innovative practices and prioritizing sustainability, we can ensure that medicines like DTG are not only effective but also environmentally responsible,” Vincent Bretin, Director of Unitaid’s Results and Climate Team told Health Policy Watch."

-via Good News Network, July 17, 2024

[daisydeborahh]

THE DOLUTEGRAVIR OPPORTUNITY

DTG is a relatively new ARV available in generic form in low- and middle-income countries. It is an integrase inhibitor that blocks an HIV enzyme (a protein that starts or increases the speed of a chemical reaction) called integrase. By blocking integrase, integrase inhibitors prevent HIV from multiplying and can reduce the amount of HIV in the body. As a single dose, in conjunction with other drugs to form a regimen, 50mg DTG single has been on the market in developing countries for a couple of years. However, its relatively high price and unavailability in a triple fixed-dose form limited significant uptake. Botswana, however, was an early adopter of the DTG single through a special initiative of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).

In August 2017, the US Food and Drug Administration (FDA) provided tentative approval for two Indian generic ARV suppliers – Aurobindo Pharma and Mylan Laboratories Limited – for the fixed-dose combination of tenofovir 300mg /lamivudine 300mg /dolutegravir 50mg (TLD), reducing one barrier for adoption in developing countries.

[covid-safer-hotties]

Reference saved in our archive

Covid's constant rapid mutation is driving a continuing pandemic. "Let 'er rip" is costing lives, money, and medicine when common-sense and highly-effective nonpharmaceuticals like masks, air filtration, and ventilation are readily available yet rarely implemented.

Highlights •There were trends of mutations in the S protein of the omicron SARS-CoV-2 variant. •The studied ARVds exhibited adequate solubility, distribution and partition coefficient. •ARVds molecularly interacted with target sites of mutations.

Abstract The multiple mutation of the spike (S) protein of the Omicron SARS-CoV-2 variant is a major concern, as it has been implicated in the severity of COVID-19 and its complications. These mutations have been attributed to COVID-19-infected immune-compromised individuals, with HIV patients being suspected to top the list. The present study investigated the mutation of the S protein of the omicron variant in comparison to the Delta and Wuhan variants. It also investigated the molecular interactions of antiretroviral drugs (ARVd) vis-à-vis dolutegravir, lamivudine, tenofovir-disoproxilfumarate and lenacapavir with the initiation and termination codons of the mRNAs of the mutated proteins of the omicron variant using computational tools. The complete genome sequences of the respective S proteins for omicron (OM066778.1), Delta (OK091006.1) and Wuhan (NC 045512.2) SARS-CoV-2 variants were retrieved from the National Center for Biotechnology Information (NCBI) database. Evolutionary analysis revealed high trends of mutations in the S protein of the omicron SARS-CoV-2 variant compared to the delta and Wuhan variants coupled with 68 % homology. The sequences of the translation initiation sites (TISs), translation termination sites (TTSs), high mutation region-1 (HMR1) and high region mutation-2 (HMR2) mRNAs were retrieved from the full genome of the omicron variant S protein. Molecular docking analysis revealed strong molecular interactions of ARVd with TISs, TTSs, HMR1 and HMR2 of the S protein mRNA. These results indicate mutations in the S protein of the Omicron SARS-CoV-2 variant compared to the Delta and Wuhan variants. These mutation points may present new therapeutic targets for COVID-19.

[pharmaceutical0]

Dolutegravir-D3 | Simson Pharma

Synonyms: Tivicay-d3;(4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1`,2`,4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide-d3

Chemical Name: (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1`,2`,4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide-d3

[freeworldallahmbaclass]

These drugs actually does cure HIV Aids and leaves the patient or person undetectable for HIV Aids so both drugs so far that I know of can cure HIV Aids . Let's do it send it to Africa for the babies think of the poor babies dying of Aids on the floor silently and crying not even talking or showing signs of pain ribs breathing in heavily from dying from starvation from hunger and something as curable as Aids again I say it to you that HIV Aids is now curable thanks to the miracle of science and doctors and thanks for giving me the platform to spread that message to the world . Maybe 50 Cent could send the drug Cabenuva and Dovato over there to Africa I read it somewhere in his new book that he is into charity with the people that I won my Nobel peace prize with me and him got together out of the world food program him with donations of water proceeds to Africa and me with my build ( my speech ) on food and nourishment food in the sense of nourishment for the mind and soul to heal the spirit and the mind a person's soul leading them into a peaceful life and way of existing instead of violence and destruction . Maybe 50 Cent could send those drugs over there through his charity you see it all the time celebrities signing big checks at a basketball game or football for some charity why not since he is hooked with the world food program and already is in Africa why not send the drug Cabenuva and Dovato since HIV Aids is now a curable disease , fact . It can be cured and that is something he said he wanted to get into curing Aids in Africa .

The cure for HIV Aids is called Dovato and my page and politics is sponsored by Vado from Harlem a very good musician and one of my favorites on the box it says that people with HIV will become undetectable for HIV which means it cures HIV Aids please let the people in Africa know and send this cure to Africa .

The story is that 50 Cent kind of dropped a hint to me on wanting to help cure the Aids epidemic in Africa and I heard it and I proposed it to send the cure for aids in Africa to the people in Africa infected with HIV Aids and this is the news headlines in March 2023 of it going through another accomplishment on my list of accomplishment thank you so much and they should be continuing sending it to Africa daily every day week month and years for generations and generations from now on a continuous basis that would be the right thing to do true humanity .

Check the news on CNN The US helped prevent AIDS from being a death sentence in Africa . The us is me and 50 Cent the rapper from his hit show power .

We did it congratulations on the cure for Aids in Africa .

The US helped prevent AIDS from being a death Sentence in Africa

Check the news on CNN on ending HIV Aids in Africa with the cure and new medicine Cabenuva HIV medicine that cures HIV Aids like the common cold and any other kind of communicable diseases

We did it congratulations on the cure for Aids in Africa .

The US helped prevent AIDS from being a death Sentence in Africa .

Cabenuva the new HIV Medicine is the cure for HIV Aids it knocks out HIV Aids like the common cold please send it to Africa to help heal the people .

[namansharma0950]

ドルテグラビル (Dolutegravir) の価格動向: 詳細なチャート、市場分析、将来の見通し

ドルテグラビル (Dolutegravir) は、HIV 感染の治療に使用される抗レトロウイルス薬です。インテグラーゼ阻害剤と呼ばれる薬剤のクラスに属します。

ドルテグラビルの価格に影響を与える要因

ドルテグラビルの価格に影響を与える要因はいくつかあります。

世界的な需要と供給: 特に HIV 感染率の高い地域での世界的な需要の変化は、価格に影響を与える可能性があります。

製造コスト: ドルテグラビルの製造にかかわる原材料、労働力、エネルギーのコストは、価格に影響を与える可能性があります。

規制環境: 政府の規制と薬価政策は、ドルテグラビルの価格に影響を与える可能性があります。

ジェネリック医薬品の競争: ジェネリック医薬品のドルテグラビルの入手可能性は、価格に影響を与える可能性があります。

リアルタイムでドルテグラビル (Dolutegravir)価格: https://www.analystjapan.com/Pricing-data/dolutegravir-2394

経済状況: インフレ、不況、為替レートなどの経済要因は、市場全体の動向と価格に影響を与える可能性があります。

ドルテグラビルの価格の将来展望

ドルテグラビルの価格は、さまざまな要因の影響を受けます。

ジェネリック医薬品の競争: ジェネリック医薬品のドルテグラビルの入手可能性が高まると、価格競争につながる可能性があります。 技術の進歩: 医薬品製造の進歩は、生産コストと価格に影響を与える可能性があります。 規制の変更: 医薬品の価格規制の変更は、ドルテグラビルの価格に影響を与える可能性があります。 市場の動向、規制の変更、技術の進歩に関する情報を常に把握しておくことで、企業は情報に基づいた決定を下し、進化するドルテグラビル市場を乗り切ることができます。

ANALYST JAPAN

Call +1 (332) 258- 6602 1-2-3 Manpukuji, Asao-ku, Kawasaki 215-0004 Japan

Website: https://www.analystjapan.com

Email: sales@analystjapan.com

[pavankalnad]

HIV treatment involves the use of Viropil Tablets, a fixed-dose combination drug. It includes three antiretroviral medications: dolutegravir (DTG), lamivudine (3TC), and tenofovir disoproxil fumarate (TDF)

[biotech-news-feed]

Opinion/decision on a Paediatric investigation plan (PIP): Dovato, lamivudine,dolutegravir, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0121/2023 #BioTech #science